Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 13,638 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Withdrawn No phase listed Observational

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

NCT03854695
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Nov 13, 2026, 3:05 AM EST
Recruiting Not applicable Interventional

UHFUS Characterization of Normal Lymphatic Anatomy

NCT07677839
View directory record Official record
Conditions
Breast Cancer
Interventions
Indocyanine green (ICG) solution injection, Ultra-High Frequency Ultrasound
Procedure · Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Completed No phase listed Observational

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)

NCT03478839
View directory record Official record
Conditions
Generalized Arterial Calcification of Infancy, Autosomal Recessive Hypophosphatemic Rickets Type2
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Year to 110 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Completed Not applicable Interventional

Impact of LOFT Therapy™ on Breast Cancer Survivors

NCT02491957
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LOFT Therapy
Other
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Nov 13, 2026, 3:05 AM EST
Completed Not applicable Interventional

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

NCT00363012
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, biopsy, Sterile water placement
Biological · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Nov 13, 2026, 3:05 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections

NCT00595881
View directory record Official record
Conditions
Abscess
Interventions
Bedside emergency ultrasound
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 18 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Nov 13, 2026, 3:05 AM EST
Completed No phase listed Observational

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

NCT02685631
View directory record Official record
Conditions
Localized Non-Resectable Adult Liver Carcinoma
Interventions
Yttrium-90 Resin Microspheres
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 13, 2026, 3:05 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

NCT07648602
View directory record Official record
Conditions
Psoriasis
Interventions
Observational (Non-Interventional) Registry
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2036
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Active, not recruiting Early Phase 1 Interventional

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

NCT04380831
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Intensity-Modulated Radiation Therapy, Total-Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Terminated Phase 1 Interventional

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions
PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 13, 2026, 3:05 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.

NCT07778472
View directory record Official record
Conditions
Healthy
Interventions
Tripelennamine, Diphenhydramine, Vehicle Control Cream Base
Drug
Lead sponsor
Palm Beach Atlantic University
Other
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Completed Phase 1 Interventional

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

NCT00631072
View directory record Official record
Conditions
Malignant Melanoma
Interventions
INKT, GM-CSF
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Nov 13, 2026, 3:05 AM EST
Not listed Phase 4 Interventional

17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts

NCT01712295
View directory record Official record
Conditions
Warts
Interventions
17% Salicylate with ethyl pyruvate, Salicylates
Drug
Lead sponsor
Grossman, Michael, D.P.M.
Individual
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Nov 13, 2026, 3:05 AM EST
Withdrawn Phase 1 Interventional

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

NCT01386502
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions
p53: 264-272 peptide, CT-011
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 13, 2026, 3:05 AM EST
Completed Not applicable Interventional

The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors

NCT02030353
View directory record Official record
Conditions
Body Weight Changes, Breast Neoplasms
Interventions
Self-regulation plus activity monitoring, Self-regulation
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Nov 13, 2026, 3:05 AM EST
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Nov 13, 2026, 3:05 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

NCT05041101
View directory record Official record
Conditions
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Eribulin Mesylate, Grapiprant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Nov 13, 2026, 3:05 AM EST
Completed Phase 1Phase 2 Interventional Results available

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

NCT01105312
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
172
States / cities
Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Nov 13, 2026, 3:05 AM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

NCT00147329
View directory record Official record
Conditions
Psoriasis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2007 · Synced Nov 13, 2026, 3:05 AM EST
Available No phase listed Expanded access

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

NCT07643831
View directory record Official record
Conditions
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Interventions
Giredestrant
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
13
States / cities
Anchorage, Alaska • Clovis, California • Fountain Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Completed Phase 4 Interventional

Quality of Life Study in Adults With Facial Eczema

NCT00120302
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Nov 13, 2026, 3:05 AM EST
Recruiting Phase 1 Interventional

[18F] F-GLN by PET/CT in Breast Cancer

NCT03863457
View directory record Official record
Conditions
Breast Cancer
Interventions
Fluoroglutamine [18F]F-GLN
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Completed Not applicable Interventional

CGM and DFU Healing Post-discharge

NCT06054659
View directory record Official record
Conditions
Diabetic Foot, Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown
Interventions
Real Time Continuous Glucose Monitoring (rt-CGM), Fingerstick blood glucose (FBG) monitoring, Diabetes Education
Device · Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 13, 2026, 3:05 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

The INFORM Study: Rotational Fractional Resection for Submental Contouring

NCT03853980
View directory record Official record
Conditions
Skin Laxity
Interventions
Focal Contouring System
Device
Lead sponsor
Recros Medica, Inc.
Industry
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Campbell, California • Encino, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Nov 13, 2026, 3:05 AM EST